Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lipitor Clear all

Conditions: Hyperlipidemia
Interventions: Placebo, MBX-8025, Atorvastatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2248761, Simvastatin, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants
Interventions: Elecoglipron, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Hypercholesterolemia, Thrombosis
Interventions: Clopidogrel, Atorvastatin; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Coronary Atherosclerosis
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 97
States / cities: Huntsville, Alabama • Los Angeles, California • Mountain View, California + 94 more

Conditions: Acute Coronary Syndrome
Interventions: intensive LDL-lowering therapy, standard statin monotherapy; Device · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 31 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Dallas, Texas

Conditions: Hypercholesterolemia
Interventions: Atorvastatin calcium 10 mg; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,311 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 37
States / cities: Hoover, Alabama • McCalla, Alabama • Pinson, Alabama + 32 more

Conditions: Cardiovascular Diseases
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Familial Hypercholesterolemia
Interventions: atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 6 Years to 15 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 3 more

Conditions: Colorectal Carcinoma, Ulcerative Colitis
Interventions: Atorvastatin Calcium, Biopsy of Colon, Biospecimen Collection, Placebo Administration, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • Kansas City, Kansas

Conditions: Human Immunodeficiency Virus
Interventions: Aspirin, Atorvastatin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Hypercholesterolaemia
Interventions: Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more

Conditions: Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions: Atorvastatin and Lisinopril, Placebo; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hearing Loss, Head and Neck Cancer
Interventions: Placebo, Atorvastatin; Other · Drug
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 80
States / cities: Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more

Conditions: Systemic Lupus Erythematosus
Interventions: atorvastatin; Drug
Lead sponsor: The Center for Rheumatic Disease, Allergy, & Immunology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Cardiovascular Diseases, Myocardial Infarction, Atherosclerotic Cardiovascular Disease, Thrombotic Vascular Disease
Interventions: Aspirin and/or Atorvastatin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Atorvastatin, MGL-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Dyslipidemia
Interventions: Atorvastatin, ABT335, ER Niacin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes
Interventions: lipitor; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 20 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Hartford, Connecticut • Storrs, Connecticut • Amherst, Massachusetts

Conditions: Graft vs Host Disease
Interventions: Atorvastatin calcium (Lipitor); Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Aortic Valve Stenosis
Interventions: atorvastatin (Lipitor); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Endometrial Cancer
Interventions: Atorvastatin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A

CRESTOR Athero Imaging Head to Head IVUS Study

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I

Actual Use Trial of Atorvastatin Calcium 10 mg

Evaluation of Atorvastatin Treatment on Carotid Plaque.

Atorvastatin Three Year Pediatric Study

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

Subclinical Cardiovascular Disease in Psoriatic Disease

Drug Interaction Study of MGL-3196 With Atorvastatin

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging

The Effect of Statin Medications on Muscle Performance (The STOMP Study)

Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation

The Effect of Lipitor on Aortic Stenosis

A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium